Treatment of cerebral ischemia by disrupting ischemia-induced interaction of nNOS with PSD-95

Nature Medicine

Volumn 16, Issue 12, 2010, Pages 1439-1444

  Zhou, Li ^a   Li, Fei ^a   Xu, Hai Bing ^a   Luo, Chun Xia ^a   Wu, Hai Yin ^a   Zhu, Ming Mei ^a   Lu, Wei ^a   Ji, Xing ^a   Zhou, Qi Gang ^a   Zhu, Dong Ya ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5 (3,5 DICHLORO 2 HYDROXYBENZYLAMINO) 2 HYDROXYBENZOIC ACID; AMINO ACID; HYDROXYBENZOIC ACID DERIVATIVE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEURONAL NITRIC OXIDE SYNTHASE; POSTSYNAPTIC DENSITY PROTEIN 95; UNCLASSIFIED DRUG; ZL 006;

AGGRESSION; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; CONTROLLED STUDY; DEATH; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; DRUG SYNTHESIS; EXCITOTOXICITY; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NERVE CELL LESION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RAT; REPERFUSION; SPATIAL MEMORY; STROKE;

ANALYSIS OF VARIANCE; ANIMALS; BIOLOGICAL TRANSPORT; BRAIN ISCHEMIA; CELL DEATH; GLUTAMIC ACID; IMMUNOPRECIPITATION; INFARCTION, MIDDLE CEREBRAL ARTERY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; MICE; MICROSCOPY, CONFOCAL; MOLECULAR STRUCTURE; NEUROPROTECTIVE AGENTS; NITRIC OXIDE SYNTHASE TYPE I; OLIGONUCLEOTIDES, ANTISENSE; RATS; RECEPTORS, N-METHYL-D-ASPARTATE; SIGNAL TRANSDUCTION; STROKE;

MUS; RATTUS;

EID: 78649983743     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2245     Document Type: Article

References (34)

1. Flynn, R.W., MacWalter, R.S. & Doney, A.S. The cost of cerebral ischaemia. Neuropharmacology 55, 250-256 (2008).
2. Gállego, J., Muñoz, R. & Martínez-Vila, E. Emergent cerebrovascular disease risk factor weighting: is transient ischemic attack an imminent threat? Cerebrovasc. Dis. 27Suppl 1, 88-96 (2009).
3. Lee, J.M., Zipfel, G.J. & Choi, D.W. The changing landscape of ischaemic brain injury mechanisms. Nature 399, A7-A14 (1999).
4. Arundine, M. & Tymianski, M. Molecular mechanisms of glutamate-dependent neurodegeneration in ischemia and traumatic brain injury. Cell. Mol. Life Sci. 61, 657-668 (2004).
5. Lipton, S.A. Pathologically activated therapeutics for neuroprotection. Nat. Rev. Neurosci. 8, 803-808 (2007).
6. Sattler, R. et al. Specifc coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science 284, 1845-1848 (1999).
7. Dawson, V.L., Kizushi, V.M., Huang, P.L., Snyder, S.H. & Dawson, T.M. Resistance to neurotoxicity in cortical cultures from neuronal nitric oxide synthase-defcient mice. J. Neurosci. 16, 2479-2487 (1996).
8. Smith, P.F. Therapeutic N-methyl-d-aspartate receptor antagonists: will reality meet expectation? Curr. Opin. Investig. Drugs 4, 826-832 (2003).
9. Muir, K.W. Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. Curr. Opin. Pharmacol. 6, 53-60 (2006).
10. Lipton, S.A. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat. Rev. Drug Discov. 5, 160-170 (2006).
11. Kelley, J.B., Balda, M.A., Anderson, K.L. & Itzhak, Y. Impairments in fear conditioning in mice lacking the nNOS gene. Learn. Mem. 16, 371-378 (2009).
12. Zhou, L. & Zhu, D.Y. Neuronal nitric oxide synthase: structure, subcellular localization, regulation, and clinical implications. Nitric Oxide 20, 223-230 (2009).
13. Aarts, M. et al. Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions. Science 298, 846-850 (2002).
14. Cao, J. et al. The PSD95-nNOS interface: a target for inhibition of excitotoxic p38 stress-activated protein kinase activation and cell death. J. Cell Biol. 168, 117-126 (2005).
15. Hecker, M., Mülsch, A. & Busse, R. Subcellular localization and characterization of neuronal nitric oxide synthase. J. Neurochem. 62, 1524-1529 (1994).
16. Rothe, F., Canzler, U. & Wolf, G. Subcellular localization of the neuronal isoform of nitric oxide synthase in the rat brain: a critical evaluation. Neuroscience 83, 259-269 (1998).
17. Brenman, J.E. et al. Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and α1-syntrophin mediated by PDZ domains. Cell 84, 757-767 (1996).
18. Cui, H. et al. PDZ protein interactions underlying NMDA receptor-mediated excitotoxicity and neuroprotection by PSD-95 inhibitors. J. Neurosci. 27, 9901-9915 (2007).
19. Takagi, N., Logan, R., Teves, L., Wallace, M.C. & Gurd, J.W. Altered interaction between PSD-95 and the NMDA receptor following transient global ischemia. J. Neurochem. 74, 169-178 (2000).
20. Cappuccio, J.A. et al. Cell-free expression for nanolipoprotein particles: building a high-throughput membrane protein solubility platform. Methods Mol. Biol. 498, 273-296 (2009).
21. Tochio, H., Hung, F., Li, M., Bredt, D.S. & Zhang, M. Solution structure and backbone dynamics of the second PDZ domain of postsynaptic density-95. J. Mol. Biol. 295, 225-237 (2000a).
22. Tochio, H. et al. Formation of nNOS/PSD-95 PDZ dimer requires a preformed beta-fnger structure from the nNOS PDZ domain. J. Mol. Biol. 303, 359-370 (2000b).
23. Chiavegatto, S. et al. Brain serotonin dysfunction accounts for aggression in male mice lacking neuronal nitric oxide synthase. Proc. Natl. Acad. Sci. USA 98, 1277-1281 (2001).
24. Huang, Z. et al. Effects of cerebral ischemia in mice defcient in neuronal nitric oxide synthase. Science 265, 1883-1885 (1994).
25. Moghaddam, B. Bringing order to the glutamate chaos in schizophrenia. Neuron 40, 881-884 (2003).
26. Gielen, M., Siegler Retchless, B., Mony, L., Johnson, J.W. & Paoletti, P. Mechanism of differential control of NMDA receptor activity by NR2 subunits. Nature 459, 703-707 (2009).
27. Koroshetz, W.J. & Moskowitz, M.A. Emerging treatments for stroke in humans. Trends Pharmacol. Sci. 17, 227-233 (1996).
28. Kemp, J.A. & McKernan, R.M. NMDA receptor pathways as drug targets. Nat. Neurosci. 5, 1039-1042 (2002).
29. Nelson, R.J. et al. Behavioural abnormalities in male mice lacking neuronal nitric oxide synthase. Nature 378, 383-386 (1995).
30. Tanda, K. et al. Abnormal social behavior, hyperactivity, impaired remote spatial memory, and increased D1-mediated dopaminergic signaling in neuronal nitric oxide synthase knockout mice. Mol. Brain 2, 19 (2009).
31. Lea, P.M., Movsesyan, V.A. & Faden, A.I. Neuroprotective activity of the mGluR5 antagonists MPEP and MTEP against acute excitotoxicity differs and does not refect actions at mGluR5 receptors. Br. J. Pharmacol. 145, 527-534 (2005).
32. Quintana, E., Hernández, C., Alvarez-Barrientos, A., Esplugues, J.V. & Barrachina, M.D. Synthesis of nitric oxide in postganglionic myenteric neurons during endotoxemia: implications for gastric motor function in rats. FASEB J. 18, 531-533 (2004).
33. Qoronfeh, M.W., Benton, B., Ignacio, R. & Kaboord, B. Selective enrichment of membrane proteins by partition phase separation for proteomic studies. J. Biomed. Biotechnol. 2003, 249-255 (2003).
34. Longa, E.Z., Weinstein, P.R., Carlson, S. & Cummins, R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20, 84-91 (1989).